A new trading data show Amneal Pharmaceuticals Inc (AMRX) is showing positive returns.

With 3.5 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.17 million shares. The 52-week range on AMRX shows that it touched its highest point at $9.48 and its lowest point at $5.01 during that stretch. It currently has a 1-year price target of $11.25. Beta for the stock currently stands at 1.05.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AMRX was up-trending over the past week, with a rise of 7.39%, but this was down by -4.42% over a month. Three-month performance surged to 1.32% while six-month performance rose 0.60%. The stock gained 45.34% in the past year, while it has gained 6.44% so far this year. A look at the trailing 12-month EPS for AMRX yields -0.68 with Next year EPS estimates of 0.71. For the next quarter, that number is 0.15. This implies an EPS growth rate of -4.30% for this year and 16.33% for next year. EPS is expected to grow by 8.17% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -23.74%.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AMRX since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.63592 being high and $0.6 being low. For AMRX, this leads to a yearly average estimate of $0.61. Based on analyst estimates, the high estimate for the next quarter is $0.21 and the low estimate is $0.14. The average estimate for the next quarter is thus $0.17.